Compare QDEL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | PGEN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2022 | 2013 |
| Metric | QDEL | PGEN |
|---|---|---|
| Price | $16.22 | $3.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $32.75 | $7.67 |
| AVG Volume (30 Days) | 1.2M | ★ 3.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $230,981,000.00 |
| Revenue This Year | $3.51 | $342.78 |
| Revenue Next Year | $3.86 | $478.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.08 | $1.11 |
| 52 Week High | $37.24 | $5.47 |
| Indicator | QDEL | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 33.62 |
| Support Level | N/A | $2.99 |
| Resistance Level | $30.65 | $5.10 |
| Average True Range (ATR) | 1.18 | 0.17 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 16.64 | 8.47 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.